Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal

Could Challenge Bluebird and CRISPR/Vertex Ex Vivo Approaches

 
• By Andrew McConaghie
Novartis Basel
Novartis: the Basel headquartered company has pioneered CAR-Ts and gene therapies and has now invested in vivo gene editing. • Source: Shutterstock

More from Business

More from Scrip